Paper2196554
Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.
Männistö PT and 1 other. Pharmacol Toxicol, 1990. Cited by 130 papers, by iCite.
Cite this record
ConductScience Library. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Papers, record 2196554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2196554
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Catechol O-Methyltransferase Inhibitors | Major topic |
| Parkinson Disease | Major topic |
| Animals | |
| Humans |
Source PubMed
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42014471 | Impact of catechol-O-methyltransferase inhibition on plasma homocysteine levels in levodopa-treated Parkinson's disease. | J Neural Transm (Vienna) | 2026 | https://conductscience.org/library/papers/42014471 | PubMed |
| 33675481 | Entacapone scavenges peroxynitrite and protects against kidney and liver injuries induced by renal ischemia/reperfusion in rats. | Int Urol Nephrol | 2021 | https://conductscience.org/library/papers/33675481 | PubMed |
| 30824559 | Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial. | Neurology | 2019 | https://conductscience.org/library/papers/30824559 | PubMed |
| 28289795 | [Pharmacological treatment of motor symptoms in Parkinson's diseases]. | Nervenarzt | 2017 | https://conductscience.org/library/papers/28289795 | PubMed |
| 27520516 | Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease. | CNS Drugs | 1994 | https://conductscience.org/library/papers/27520516 | PubMed |
| 24460628 | Comprehensive interrogation of CpG island methylation in the gene encoding COMT, a key estrogen and catecholamine regulator. | BMC Med Genomics | 2014 | https://conductscience.org/library/papers/24460628 | PubMed |
| 19628038 | NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells. | J Steroid Biochem Mol Biol | 2009 | https://conductscience.org/library/papers/19628038 | PubMed |
| 17894650 | Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. | CNS Drug Rev | 2007 | https://conductscience.org/library/papers/17894650 | PubMed |
| 12959293 | The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. | Br J Clin Pharmacol | 1993 | https://conductscience.org/library/papers/12959293 | PubMed |
| 11994054 | Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. | Br J Clin Pharmacol | 2002 | https://conductscience.org/library/papers/11994054 | PubMed |
| 10882160 | Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. | Drugs | 2000 | https://conductscience.org/library/papers/10882160 | PubMed |
| 10516661 | Catechol-O-methyltransferase activity in CHO cells expressing norepinephrine transporter. | Br J Pharmacol | 1999 | https://conductscience.org/library/papers/10516661 | PubMed |
| 10510160 | COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet). | Br J Clin Pharmacol | 1999 | https://conductscience.org/library/papers/10510160 | PubMed |
| 10408739 | Does levodopa accelerate Parkinson's disease? | Drugs Aging | 1999 | https://conductscience.org/library/papers/10408739 | PubMed |
| 10323601 | In vivo effects of new inhibitors of catechol-O-methyl transferase. | Br J Pharmacol | 1999 | https://conductscience.org/library/papers/10323601 | PubMed |
| 9203084 | Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. | J Neural Transm (Vienna) | 1997 | https://conductscience.org/library/papers/9203084 | PubMed |
| 8877311 | New directions in the drug treatment of Parkinson's disease. | Drugs Aging | 1996 | https://conductscience.org/library/papers/8877311 | PubMed |
| 8785021 | Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. | J Neural Transm Gen Sect | 1995 | https://conductscience.org/library/papers/8785021 | PubMed |
| 8527287 | Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. | Br J Clin Pharmacol | 1995 | https://conductscience.org/library/papers/8527287 | PubMed |
| 8126502 | Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. | J Neurol Neurosurg Psychiatry | 1994 | https://conductscience.org/library/papers/8126502 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2196554
GET https://conductscience.org/api/papers/v1/2196554/cited_by?page=2